Unfolded protein response (UPR) is an adaptive reaction that allows cancer cells to survive endoplasmic reticulum (EnR) stress that is often induced in the tumor microenvironment because of inadequate vascularization. Previous studies report an association between activation of the UPR and reduced sensitivity to antiestrogens and chemotherapeutics in estrogen receptor α (ERα)positive and triple-negative breast cancers, respectively. ERα has been shown to regulate the expression of a key mediator of the EnR stress response, the X-box-binding protein-1 (XBP-1). Although network prediction models have associated ERβ with the EnR stress response, its role as regulator of the UPR has not been experimentally tested. Here, upregulation of wild-type ERβ (ERβ1) or treatment with ERβ agonists enhanced apoptosis in breast cancer cells in the presence of pharmacological inducers of EnR stress. Targeting the BCL-2 to the EnR of the ERβ1-expressing cells prevented the apoptosis induced by EnR stress but not by non-EnR stress apoptotic stimuli indicating that ERβ1 promotes EnR stress-regulated apoptosis. Downregulation of inositol-requiring kinase 1α (IRE1α) and decreased splicing of XBP-1 were associated with the decreased survival of the EnR-stressed ERβ1-expressing cells. ERβ1 was found to repress the IRE1 pathway of the UPR by inducing degradation of IRE1α. These results suggest that the ability of ERβ1 to target the UPR may offer alternative treatment strategies for breast cancer.
INTRODUCTION
Implementation of screening programs and novel treatment approaches have led to a decrease in breast cancer mortality. Nonetheless, approximately 40 000 breast cancer-associated deaths are estimated to occur in the United States in 2014. [1] [2] [3] Despite the heterogeneity of breast cancer with respect to molecular alterations and treatment sensitivity, there are only a few well-validated prognostic markers and therapeutic targets for the clinical management of the disease. Treatment with the antiestrogen tamoxifen, which binds to estrogen receptor α (ERα) and alters conformation of helix 12 relative to that seen with 17βestradiol (E2), is a standard treatment option for the nearly 70% of breast tumors that express this receptor. Although this treatment has been shown to reduce breast cancer mortality by one-third, not all breast cancers respond to endocrine therapy. 4 Adaptive mechanisms that provide tumor cells with alternative survival possibilities can confer therapeutic resistance. One mechanism of resistance is the unfolded protein response (UPR). 5 UPR is an adaptive response that is activated in tumor cells because of the limited capacity of the tumor microenvironment to supply the tumor with adequate levels of nutrients and oxygen. This leads to the accumulation of unfolded proteins in the endoplasmic reticulum (EnR), a condition known as EnR stress. Activation of the UPR restores EnR homeostasis by increasing protein folding, enhancing degradation of misfolded proteins and inhibiting protein synthesis, thus adjusting the protein folding capacity of the EnR to the folding demand. 6, 7 In the absence of EnR stress, the major transducers of the UPR, PKR-like EnR localized kinase, activating transcription factor 6 and inositol-requiring kinase 1 (IRE1) are inactive because of their interaction with the chaperone glucose-regulated protein 78-kDa (GRP78, also known as BIP or HSPA5). In response to EnR stress, GRP78 dissociates from the above substrates to interact with the unfolded proteins to facilitate their proper folding. 8, 9 Upon dissociation from GRP78, IRE1α, which is an EnR transmembrane protein with functional kinase and endonuclease domain, undergoes dimerization, autophosphorylation and activation of its endonuclease activity. Active IRE1α splices a 26-nucleotide intron form X-box-binding protein-1 (XBP-1) mRNA, which, through a translational frame-shift, results in the expression of a strong transcription factor-the activated/spliced form of XBP-1 (XBP--1s). 10, 11 XBP-1s binds to EnR stress response element to induce the expression of genes that are involved in the EnR-associated degradation as well as those promoting protein folding. 12, 13 Activation of the UPR serves to protect the EnR and the entire cell from the accumulation of unfolded proteins. Downregulation of the UPR under conditions that promote EnR stress can initiate apoptosis. The apoptotic response during the EnR stress utilizes both intrinsic and extrinsic pathways. Upregulation of the C/EBPhomologous protein induces apoptosis in response to EnR stress by decreasing the levels of the anti-apoptotic protein BCL-2. Downregulation of BCL-2 results in mitochondrial release of cytochrome c and the subsequent activation of the cytosolic caspase-dependent pro-apoptotic cascade. 14 Activation of the UPR has been associated with therapeutic resistance and recurrence in several types of cancer including breast cancer. GRP78 has been shown to confer resistance to estrogen starvation-induced apoptosis 15 and to antiestrogens 16 in breast cancer cells and its expression predicts response to taxanebased adjuvant chemotherapy in breast cancer patients. 17 Similarly, XBP-1 is overexpressed in endocrine-resistant breast cancer cells, 18 confers resistance to antiestrogens 19 and correlates with responses to tamoxifen in breast cancer patients. 20 High expression of ERα and XBP-1 is part of the gene expression signature in luminal breast cancers and ERα is known to bind the promoter of the XBP-1 gene inducing its transcription. 1, 21 XBP-1s also induces an estrogen-independent transcriptional activation of ERα. 22 In addition to ERα-positive breast cancers, activation of XBP-1 has recently been associated with tumor progression and chemotherapy response in triple-negative breast cancer. 23 Although the association of ERα with the activation of the EnR stress response has been established, the role of ERβ in regulating the UPR is currently unknown. Wild-type ERβ (ERβ1) has been shown to inhibit the growth and decrease the invasiveness of breast cancer cells. 4, 24 Further, clinical studies have reported an association between ERβ1 expression and better overall survival in breast cancer. Interestingly, patients with triple-negative breast cancer that were treated with adjuvant tamoxifen have significantly better survival when their tumors are positive for ERβ1. 25 In the present study, we investigated whether, by regulating the UPR, ERβ1 alters the resistance of breast cancer cells to EnR stress. ERβ1 was found to sensitize breast cancer cells to EnR stressregulated apoptosis by repressing the IRE1 pathway of the UPR.
RESULTS

ERβ1 decreases the survival of breast cancer cells in response to
EnR stress Activation of the UPR in breast cancer cells has been associated with reduced sensitivity to antiestrogens 26 and chemotherapeutics. 5, 17, 23 ERα, the principal biomarker for directing endocrine therapies, also regulates the expression of XBP-1. 4, 21 Although network modeling approaches predict a potential relationship of ERβ with XBP-1 in breast cancer, 27 the role of the second estrogen receptor in the context of UPR-regulated cell survival has not been experimentally tested. We hypothesized that the wild-type form of the receptor affects the sensitivity of breast cancer cells to EnR stress-induced apoptosis by regulating the UPR. To test this hypothesis, we stably expressed ERβ1 in two breast cancer cell lines, the ERα-positive MCF-7 cells and the triplenegative MDA-MB-231 cells (Figure 1a ). MCF-7 cells express high levels of ERα and relatively low levels of ERβ1. The levels of ERβ1 in MCF-7 cells are higher compared with those in MDA-MB-231 cells. 24, 28 Cells were analyzed for cell survival following exposure to two pharmacological inducers of EnR stress, the Ca 2+ -ATPase inhibitor thapsigargin (Tg) and the proteosomal inhibitor bortezomib (BZ). BZ has received approval from the US Food and Drug Administration for use in the treatment of patients with multiple myeloma and mantle cell lymphoma. 29 As shown in Figures 1b and c, treatment with Tg or BZ for 30 h decreased the number of both control and ERβ1-expressing cells. However, the effect of the drugs was significantly more potent in ERβ1-expressing cells compared with the control cells, suggesting the involvement of ERβ1 in the mechanisms that regulate cell survival in response to EnR stress. Interestingly, the ERβ1-mediated decrease of survival was much greater in triple-negative as compared with ERαpositive breast cancer cells.
To elucidate the mechanism through which ERβ1 reduced breast cancer cell survival in response to EnR stress, breast cancer cells with different ERβ1 levels were treated with BZ or Tg for 24 h and analyzed for apoptosis by flow cytometry. Upregulation of ERβ1 dramatically enhanced apoptosis in response to either BZ or Tg treatment as shown by the higher percentage of BZ-or Tgtreated, ERβ1-expressing MDA-MB-231 cells in sub-G1 fraction that is indicative of apoptosis ( Figure 1d , left and right). To strengthen the pro-apoptotic effect of ERβ1, we assessed apoptosis in MDA-MB-231 cells with differential expression of ERβ1. Gradual upregulation of ERβ1 in the presence of EnR stress resulted in a progressive increase of the sub-G1 cell population (Supplementary Figure 1A) . Quantification of ERβ1 expression shows that about 50% of the amount of the receptor that is expressed in our ERβ1expressing cell model is sufficient to sensitize the cells to EnR stressors. In addition to a serial increase of ERβ1 expression, MCF-7 cells were transiently transfected with control or ERβ small interfering RNA (siRNA) and the sub-G1 cell fraction was measured following treatment with a concentration of Tg that significantly enhanced apoptosis in control cells. Downregulation of ERβ1 rescued the cells from the Tg-induced apoptosis confirming the pro-apoptotic function of the receptor in EnR-stressed breast cancer cells ( Figure 1e ). To examine whether the ERβ splice variant ERβ2, which differs from ERβ1 in 26 C-terminal amino acids, sensitizes breast cancer cells to EnR stress, we assessed apoptosis in EnR-stressed control and ERβ2-expressing MDA-MB-231 cells. As shown in Supplementary Figure 1B , in contrast to ERβ1, upregulation of ERβ2 failed to significantly induce apoptosis in response to EnR stress in breast cancer cells. To test whether ERβ1 sensitizes breast cancer cells to other cell death inducers, we analyzed control and ERβ1-expressing MDA-MB-231 cells for apoptosis following treatment with staurosporine, a kinase inhibitor that induces apoptosis. 30 Under staurosporine treatment, the sub-G1 fraction of ERβ1-expressing cells was significantly higher compared with that of the control cells, suggesting that ERβ1 increases the cytotoxic effect of staurosporine in breast cancer cells (Supplementary Figure 1C ). This stress-dependent proapoptotic effect of ERβ1 is consistent with our previous findings showing increased sensitivity of breast cancer cells to DNAdamaging agent cisplatin following upregulation of ERβ1. 31 ERβ1 sensitizes breast cancer cells to EnR stress-induced apoptosis Defective UPR activation upon cell exposure to EnR stress can trigger apoptosis through activation of mitochondrial pathways that stimulate caspase-dependent and -independent cascades. 14 To investigate whether ERβ1 activated mitochondria-dependent pro-apoptotic pathways in EnR-stressed breast cancer cells, control and ERβ1-expressing MDA-MB-231 cells were left untreated or treated with Tg and the cleavage of caspase-3 was evaluated by immunoblotting. Consistent with the ERβ1-induced apoptosis observed under EnR stress in flow cytometry histograms, the cleavage of caspase-3 was markedly accelerated in ERβ1-expressing cells, yielding high levels of cleaved caspase-3 after 18 h of Tg treatment. In contrast, 18 h post EnR stress, cleaved caspase-3 was not detected in control cells (Figure 2a ). In addition, we assessed the activation of the pro-apoptotic marker poly-ADP ribose polymerase (PARP) in MCF-7 cells that express caspase 7 but do not express caspase-3. 32 As shown in Figure 2b , the kinetics of PARP activation in EnR-stressed MCF-7 cells were similar to those of caspase-3 in MDA-MB-231 cells further supporting our initial hypothesis that ERβ1 induces apoptosis in response to EnR stress.
To ascertain the effect of activating endogenous ERβ1 in apoptosis, we treated wild-type and ERβ1-overexpressing MCF-7 cells with ER subtype-selective ligands together with EnR stress inducer. Apoptosis was then measured by monitoring the cleaved form of PARP by immunoblotting. As shown in Figure 2c , the ERβspecific agonist diarylpropionitrile (DPN) was the only ER subtypeselective ligand that significantly increased the levels of cleaved PARP in both cell types. Consistent with these results, following downregulation of ERβ1, the levels of cleaved PARP were significantly lower in DPN-treated MCF-7 cells as compared with the cells treated with E2 or propyl pyrazole triol (PPT; Figure 2d ), supporting a specific pro-apoptotic role for ERβ in EnRstressed cells.
To confirm that ERβ1 induces EnR stress-regulated apoptosis, we targeted the anti-apoptotic factor BCL-2 to EnR in ERβ1-expressing MDA-MB-231 cells by stably expressing BCL-2 containing the EnR-targeting sequence of cytochrome b5 (BCL--2cb5). BCL-2 targeted exclusively to the EnR has been shown to suppress cell death induced by EnR stress agents. 14 BCL-2 family members are known to be key determinants of cell survival in response to both antiestrogens 33 and taxanes. 34 ERβ1-expressing cells stably transfected with BCL-2cb5 plasmid or an empty control vector were treated with Tg or the non-EnR genotoxic stressor cisplatin and apoptosis was evaluated by fluorescence-activated cell sorting (FACS) analysis and by assessing the cleavage of caspase-3. The stably transfected BCL-2cb5 showed EnR localization, as determined by its similar localization pattern with that of the DsRed fluorescent protein containing the EnR-targeted sequence of calreticulin and the EnR retention sequence KDEL (Figure 2e ). Upregulation of EnR-related BCL-2 did not rescue the ERβ1-expressing cells from the cisplatin-induced apoptosis as shown by a similar increase in the sub-G1 fraction and of cleaved caspase-3 in the cells carrying the empty vector and those expressing BCL-2cb5. In contrast, expression of BCL-2cb5 reversed the Tg-induced apoptosis in ERβ1-expressing cells (Figure 2f ), suggesting that the apoptosis observed in ERβ1-expressing breast cancer cells was EnR stress-regulated apoptosis.
ERβ1 downregulates EnR stress-induced XBP-1 splicing in breast cancer cells XBP-1 can activate ERα 22 and confer both estrogen-independence and antiestrogen resistance on breast cancer cells. 19, 20 The survival of XBP-1-deficient cells is compromised under conditions that induce EnR-stress. 6 Given that EnR stress induces splicing of XBP-1 and ERβ1 decreased the survival of EnR-stressed breast cancer cells, we explored the putative role of ERβ1 in the regulation of XBP-1 processing. We treated control and ERβ1expressing breast cancer cells with Tg or BZ and assessed XBP-1 splicing by immunoblotting, real-time PCR and RT-PCR in timecourse experiments. XBP-1 splicing is activated early (within a few hours) in the course of the EnR stress response. 35 As shown in (Figure 3d ). In contrast to XBP-1s, ERβ1 did not alter the expression of the unspliced form of XBP-1 in the absence of EnR stress, indicating that ERβ1 may not regulate the transcription of the XBP-1 gene (Figure 3e ).
We then investigated the effect of endogenous ERβ1 downregulation on XBP-1 splicing in EnR-stressed MCF-7 cells. Real-time PCR revealed a notable increase of the XBP-1s mRNA in the cells transfected with ERβ-specific siRNA compared with the control cells in response to Tg treatment (Figure 3f ). To explore the impact of endogenous ERβ1 activation on splicing of XBP-1, we treated wild-type and ERβ1-overexpressing MCF-7 cells with estrogen receptor subtype-selective ligands for 24 h with or without Tg for 4 h and assessed the levels of XBP-1s by immunoblotting and realtime PCR. As shown in Figure 4a and Supplementary Figure 2B , in the presence of EnR stress, the highest levels of XBP-1s were observed in the cells treated with E2 and the ERα-specific ligand PPT; the lowest levels were seen in cells treated with the ERβspecific agonist DPN and the ERα antagonist ICI 182780. In the absence of Tg, an increase in the spliced form of XBP-1 was again observed in the cells treated with E2 and PPT (Supplementary Figure 2C ). In addition to XBP-1s, E2 was found to induce expression of the unspliced form of XBP-1 in the absence of EnR stress, data consistent with previous studies showing E2-induced transcription of XBP-1 in breast and endometrial cancer cells (Supplementary Figure 2D ). 21 Although E2 binds both ER subtypes with a similar affinity, the higher expression of ERα may determine the effect of the ligand on the regulation of UPR in MCF-7 cells. To strengthen the association of DPN with the downregulation of XBP-1s, we assessed the expression of XBP-1s in EnR-stressed MCF-7 cells that were transiently transfected with control or ERβ siRNA and treated with DPN. Importantly, DPN was found to fully reverse the Tg-mediated upregulation of XBP-1s in cells that express ERβ1 but not in the cells in which ERβ1 was downregulated ( Figure 4b ). To examine whether the ERα antagonist ICI 182780 alters the DPN-mediated downregulation of XBP-1s, we measured the expression of XBP-1s in EnR-stressed MCF-7 cells after treatment with DPN and ICI 182780. As shown in Figure 4c , ICI 182780 did not reverse the effect of DPN on XBP-1s expression, suggesting that ICI 182780 may act through a mechanism that involves inhibition of ERα and/or activation of ERβ1. To further corroborate the role of ERβ1 on the regulation of XBP-1 splicing, we assessed UPR downstream responses in control and ERβ1expressing breast cancer cells in time-course experiments. Treatment of control MDA-MB-231 and MCF-7 cells with Tg led to a more pronounced upregulation of the XBP-1s target genes ERdj4 and P58IPK when compared with ERβ1-expressing cells (Figures 4d and e, left and right) . Taken together, these results suggest that ERβ1 may repress the UPR by reducing the splicing of XBP-1.
ERβ1 regulates the expression of IRE1α in breast cancer cells
To study possible involvement of IRE1α in the ERβ1-mediated regulation of XBP-1 splicing under EnR stress, we assessed IRE1α expression in control and ERβ1-expressing breast cancer cells following treatment with Tg. Immunoblotting revealed a strong decrease in IRE1α protein levels in ERβ1-expressing MDA-MB-231 cells both in the absence and presence of Tg when compared with the control cells (Figure 5a, left) . In contrast to IRE1α protein levels, induction of ERβ1 expression caused a reduction in the IRE1α mRNA only in EnR-stressed cells (Figure 5a , right). Decreased IRE1α protein levels were also detected in the MCF-7 cells following upregulation of ERβ1 (Figure 5b ).
As downregulation of IRE1α in unstressed ERβ1-expressing cells was observed only at the protein level, we set out to investigate whether ERβ1 regulates degradation of the IRE1α protein. In chase experiments, induction of ERβ1 expression in MDA-MB-231 cells reduced the half-life of IRE1α, suggesting that IRE1α protein turnover was enhanced by ERβ1 (Figure 5c, left and right) . Treatment of the cells with the proteasome inhibitor MG-132 inhibited the ERβ1-mediated decrease in IRE1α protein abundance confirming that IRE1α downregulation in ERβ1-expressing cells was due to increased degradation (Figure 5d , left and right). IRE1α degradation occurs through a process that involves ubiquitylation by the E3 ubiquitin ligase synoviolin 1 (SYVN1) and dissociation from the molecular chaperone HSP90. 36, 37 Interestingly, elevated SYVN1 expression correlates with decreased levels of IRE1α 36 and E2 regulates the expression of Syvn1 gene in mouse uterus. 38 Induction of ERβ1 expression caused a significant increase in the levels of SYVN1 in MDA-MB-231 cells (Figure 5e ). In addition to upregulation of SYVN1, immunoprecipitation of HSP90 under nondenaturing conditions showed a decreased recruitment of IRE1α to HSP90 in ERβ1-expressing MDA-MB-231 cells as compared with the control cells (Figure 5f ), implying the involvement of SYVN1 and HSP90 in the ERβ1-mediated regulation of IRE1α pathway.
ERβ1 sensitizes tamoxifen-resistant breast cancer cells to EnR stress and tamoxifen by downregulating the UPR Tamoxifen-resistant breast cancer cells overexpress both XBP-1 18 and the master regulator of the EnR stress response GRP78; downregulation of GRP78 was found to restore antiestrogen sensitivity in resistant cells. 16 Given the downregulation of the IRE1α branch of the UPR in ERβ1-expressing breast cancer cells, we hypothesized that ERβ1 can decrease the survival of the antiestrogen-resistant cells in response to EnR stress. To test this, we used as a model of endocrine resistance the MCF-7-RR cells that are estrogen-independent and tamoxifen-resistant. These cells were derived from MCF-7 cells following selection in low serum and tamoxifen. 39 Analysis of ERβ1 expression revealed significantly lower levels of the receptor in the tamoxifen-resistant cells as compared with the sensitive cells suggesting its involvement in the mechanisms that regulate therapeutic resistance in breast cancer (Figure 6a ). Following stable expression of ERβ1 by lentiviral transduction and mass selection, we treated control and ERβ1-expressing cells with Tg and BZ for 30 h or the active metabolite of tamoxifen, 4-hydroxytamoxifen, for 3 days. Induction of ERβ1 expression decreased viability of the resistant cells in the presence of the EnR stress inducers and 4hydroxytamoxifen ( Figure 6b ). Finally, time-course experiments showed elevated cleaved PARP and decreased expression of IRE1α and splicing of XBP-1 in Tg-treated ERβ1-expressing cells as compared with the Tg-treated control cells suggesting that ERβ1 sensitizes antiestrogen-resistant cells to EnR stress-induced apoptosis by downregulating the UPR (Figures 6c and d and Supplementary Figures 3A and B) . 
DISCUSSION
Previous studies report activation of the UPR in breast tumors. The expression of GRP78 and the increased activity of the IRE1/XBP-1 pathway have been associated with progression and therapeutic resistance in breast cancer. 16, 17, 20, 23 Regulation of XBP-1 expression has been shown to be critical in sustaining hormone-induced growth in breast cancer cells. The expression of XBP-1 is regulated by estrogen and ERα is recruited at the promoter and/or enhancer region of the XBP-1 gene. 21 In addition to ERα, ERβ mediates estrogen signaling and is also expressed in many breast cancers. The expression of ERβ has been associated with sensitivity to tamoxifen treatment and clinical outcome in breast cancer. 4, 25 However, the molecular mechanism that accounts for this association is not fully understood. We initially observed that ERβ1 is expressed at lower levels in tamoxifen-resistant breast cancer cells compared with sensitive cells. As activation of the UPR has been detected in resistant cells, we hypothesized that the downregulation of ERβ1 may be associated with the activation of the EnR stress response. This hypothesis was further supported by previous studies proposing a predicted association of ERβ with markers of the UPR. 5, 27 Based on this information, we investigated whether ERβ affects cell growth in ERα-positive and triple-negative breast cancer cells by regulating the EnR stress response. Assessment of cell viability under conditions that induce EnR stress led to the conclusion that ERβ1 decreases the survival of both antiestrogen-sensitive and -resistant breast cancer cells. Further analysis of the same cells revealed that their increased sensitivity was due to ERβ1-mediated induction of apoptosis. Importantly, in addition to the EnR stress inducers, re-expression of ERβ1 in the tamoxifen-resistant cells increased their sensitivity to tamoxifen treatment. This observation is consistent with previous studies showing induction of apoptosis in tamoxifentreated antiestrogen-sensitive breast cancer cells following upregulation of ERβ1. 40 In contrast to ERβ1, upregulation of ERβ2 did not induce apoptosis in EnR-stressed breast cancer cells. Thus, the ERβ isoforms perform different roles in apoptosis and survival in breast cancer cells that may explain their different prognostic value in breast cancer patients. 41 Expression of ERβ1 in cancer cells that express very low levels of endogenous ERβ1, such as MDA-MB-231 cells, has been reported to elicit tumor repressive actions in a ligand-independent manner. Assessment of estrogen response element-dependent transcriptional activity by estrogen response element-luciferase-based reporter assay has shown increased activity in ERβ1-transfected cells following treatment with ER ligands. However, the expression of cancer-related genes was not altered significantly in the presence of ligands, implying the involvement of other transcription factors in ERβ1 action. 24, 31, 42, 43 In contrast, ligand-dependent effects of ERβ have been observed in cancer cells that express endogenous ERβ1 including MCF-7 cells. 28, 44 The expression levels of the receptor, ERα and coregulatory proteins in transfected cells and in cells that express endogenous ERβ1 may be important factors in determining the type of effect (ligand-independent or -dependent) that ERβ1 elicits in cancer cells. Expecting liganddependent ERβ1-mediated regulation of the EnR stress response in MCF-7 cells that express both ERα and ERβ1, we measured apoptosis in EnR-stressed MCF-7 cells following treatment with estrogen receptor subtype-selective ligands. As expected, only the ERβ-specific agonist significantly upregulated markers of apoptosis. Ligand-dependent ERβ1-mediated upregulation of apoptotic factors in response to EnR stress suggests the use of specific ERβ1 agonists together with EnR stress inducers as a potential treatment modality for the clinical management of the therapeutic resistance in breast cancer. The EnR stress inducer BZ has been used for the treatment of patients with metastatic breast cancer in a phase II study. 45 Interestingly, BZ inhibited bone tumor growth of the metastatic triple-negative MDA-MB-231 cells in a mouse xenograft model. 46 Our finding showing robust induction of apoptosis in BZ-treated MDA-MB-231 cells following upregulation of ERβ1 provides the molecular basis for a novel strategy based on combined use of ERβ agonists and BZ to treat patients with metastatic breast cancer.
Downregulation of the UPR in cells that experience EnR stress is known to trigger apoptosis. 14 Our results suggest that the apoptosis induced in ERβ1-expressing EnR-stressed cells was due to repression of the EnR stress response. Importantly, upregulation of ERβ1 or treatment with its specific agonist DPN were found to decrease the expression of the EnR stress transducer XBP-1s and that of its target genes. Downregulation of XBP-1s was also observed when the EnR-stressed cells were treated with ICI 182780 that is known to act as an antagonist for ERα and to induce the ERβ1-mediated tumor repressive actions. 47, 48 A dual role of this ligand as antagonist for ERα and agonist of ERβ1 may account for its effects on UPR in EnR-stressed breast cancer cells that express both receptors. In contrast, ERα agonists upregulated XBP-1s in ERα-positive breast cancer cells, which is consistent with previous studies demonstrating that XBP-1 transcription is stimulated by E2. 21 These findings strengthen the idea that XBP-1 is an estrogen-regulated gene. In addition, our observation that ERβ1 represses the expression of XBP-1s in both ERα-positive and triple-negative breast cancer cells suggests that ERβ1 regulates the EnR stress response through a mechanism that does not necessarily involve regulation of ERα activity. Interestingly, increased expression of XBP-1s has also been associated with tumorigenicity and recurrence in triplenegative breast cancer. Depletion of XBP-1 decreased cancer cell invasiveness and increased tumor chemosensitivity in a triple- negative breast cancer xenograft model. 23 We have previously shown that ERβ1 decreases the invasiveness of triple-negative breast cancer cells and increases their sensitivity to treatment with chemotherapeutic drugs. 24, 31 Our finding that ERβ1 downregulates XBP-1s in triple-negative breast cancer cells may account for the phenotypes observed in ERβ1-expressing triple-negative breast cancer cells and provides a rational for the use of ERβspecific agonists as therapeutic agents to treat patients with this aggressive subtype of breast cancer.
The spliced form of XBP-1 is produced upon activation of the EnR stress transducer IRE1α. 6 We investigated whether inactivation of IRE1α is associated with decreased XBP-1s in ERβ1expressing cells. Indeed, decreased protein levels of IRE1α were detected in ERβ1-expressing cells both in the absence and the presence of EnR stress. Further analysis of IRE1α expression revealed downregulation of IRE1α mRNA in ERβ1-expressing cells only in the presence of EnR stress, indicating a transcriptional regulation of IRE1α by ERβ1. However, the decreased protein levels of IRE1α in the same cells in the absence of EnR stress supports a model that involves post-transcriptional regulation of IRE1α by ERβ1. IRE1α expression is regulated at post-transcriptional level through increased ubiquitylation and degradation. Upregulation of the E3 ubiquitin ligase SYVN1 and IRE1α-HSP90 dissociation have been shown to promote IRE1α degradation. 36, 37 The enhanced protein turnover of IRE1α, the decreased IRE1α-HSP90 association and the increased expression of SYVN1 detected in ERβ1-expressing cells suggest that ERβ1 induces degradation of IRE1α. This is the first demonstration that ERβ1 decreases the survival of EnR-stressed breast cancer cells by downregulating the UPR (Figure 6e ). These results may shed more light into the mechanisms that regulate therapeutic resistance in breast cancer and explain the association between the expression of ERβ1 and sensitivity to endocrine therapy observed in clinical studies with breast cancer patients. Further understanding of the mechanisms that repress the expression of IRE1α, downregulate the UPR and decrease cell survival in ERβ1-expressing cells in response to EnR stress should establish ERβ1 as an important regulator of the stress response in breast cancer and the clinical management of the disease.
MATERIALS AND METHODS
Cells and reagents
Breast cancer cell lines (MDA-MB-231 and MCF-7) and H1299 lung cancer cells were obtained from American Type Culture Collection (Manassas, VA, USA). The cells were cultured in RPMI-1640 (MDA-MB-231, H1299) and Dulbecco's modified Eagle's medium (MCF-7) media supplemented with 10% fetal calf serum (FCS). Tamoxifen-resistant MCF-7 cells (MCF-7-RR) were kindly provided by Dr R Clarke (Georgetown University). These cells were grown in phenol red-free Iscove's modified Eagle medium media (Invitrogen, Carlsbad, CA, USA) supplemented with 5% dextran-coated charcoal (DCC)-treated FCS (DCC-FCS) and 4-hydroxytamoxifen (Sigma-Aldrich, St Louis, MO, USA). 39, 49 Cells were infected with lentivirus containing the empty pLenti6/V5 vector or the recombinant pLenti6/V5-D-FLAG-ERβ1, -ERβ2 and -ERα plasmids as previously described. 42 Serial increase of ERβ1 expression in MDA-MB-231 cells was achieved by single and repeated lentiviral transduction. MCF-7 cells were transiently transfected twice with ERβ-specific siRNAs (Invitrogen), target sequences 1# 5′-TTAGCGACGTCTGTCGCGTCTTCAC-3′ and 2# 5′-TTACGACATTAAGTA GTGTCGTCCC-3′. An siRNA-targeting luciferase was used as a control (12935-146, Invitrogen). For the expression of EnR-targeted BCL-2, ERβ1expressing MDA-MB-231 cells were stably transfected with the pIRESpuro-BCL-2cb5 expression plasmid that contains the full-length human BCL-2 cDNA with a deletion at the C-terminal 658-720 base pairs (corresponding to amino acids 210-239) ligated to the EnR-targeting signal sequence of human cytochrome b5. Cells were treated with the EnR-stress inducers Tg and BZ, the genotoxic agent cisplatin, the kinase inhibitor staurosporine (Sigma-Aldrich), the estrogen receptor subtype-selective ligands E2, DPN, PPT, the estrogen receptor antagonist ICI 182780 (Tocris Biosciences, Bristol, UK) and the antiestrogen 4-hydroxytamoxifen in phenol red-free media containing 5% DCC-FCS.
Cell survival assay
Cells were plated at a density of 7.5 × 10 5 cells per 35-mm dish. After 24 h, cells were treated with vehicle or EnR stress inducers in 5% DCC-FCS media for 30 h. Cells were initially imaged using x20 objective in an OLYMPUS IX51 microscope equipped with an OLYMPUS XM10 camera (OLYMPUS, Center Valley, PA, USA) and then were harvested by trypsinization and stained with 0.4% trypan blue solution (Sigma-Aldrich). Viable cells were counted using Hausser Levy Hemocytometer (ThermoFisher Scientific, Waltham, MA, USA). In some of the experiments, cell viability was assessed in cell lysates following nucleic acid staining with blue-fluorescent Hoechst 33258 using the FluoReporter Blue Fluorometric dsDNA Quantification Kit (Life Technologies). Fluorescence was measured in a PerkinElmer 2030 multilabel reader (Perkin Elmer, Waltham, MA, USA).
FACS analysis
Cells were harvested by trypsinization, washed with PBS, fixed in 70% ethanol and incubated with propidium iodide as previously described. 50 Cells were analyzed for DNA content in a FACS Aria II cell sorter (BD Biosciences, San Jose, CA, USA). Histogram resolutions were analyzed with FlowJo.10 cell cycle analysis software (Tree Star, Ashland, OR, USA).
Immunoblotting-immunoprecipitation
Whole-cell lysates were prepared in radioimmunoprecipitation assay buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% SDS, 0.5% deoxycholate and 1% NP-40) containing protease (1 mM EDTA, Roche protease inhibitor mixture (Roche, Branchburg, NJ, USA), 2 mM PMSF) and phosphatase inhibitors (1 mM NaF, 1 mM Na3VO4, Sigma phosphatase inhibitor mixture). The lysates were subjected to SDS-polyacrylamide gel electrophoresis and transferred onto nitrocellulose membrane (Amersham Biosciences, Pittsburgh, PA, USA). Membranes were blocked with 5% blotting-grade blocker (Bio-Rad, Hercules, CA, USA) in TBST (0.05% Tween-20) for 3 h at room temperature and probed with the primary antibodies overnight at 4°C. Proteins were visualized using ECL detection kit (Amersham Biosciences) following incubation of the membranes with secondary antibodies for 2 h at room temperature. Primary antibodies against XBP-1 and BCL-2 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). A second antibody against XBP-1 (clone: Poly6195) was from BioLegend (San Diego, CA, USA). The antibodies against IRE1α, ERα, caspase-3 and PARP were from Cell Signaling (Danvers, MA, USA), the anti-actin-β from Sigma-Aldrich and the antibodies against P84 and ERβ1 (clone 14C8) were from GeneTex (Irvine, CA, USA). The 14C8 antibody, which is against the N-terminus of ERβ, detects both ERβ1 and ERβ2 and has been validated for its specificity. 24, 43 In addition to recombinant ERβ1 protein, as a positive control of untagged ERβ1 expression, lysates from H1299 lung cancer cells that had been stably transfected with pIRES-ERβ1 plasmid and validated for ERβ1 expression using different ERβ antibodies were loaded in some of the gels. 43 For the IRE1α-HSP90 co-immunoprecipitations, cells were lysed in a buffer containing 50 mM HEPES, pH 7.4, 150 mM NaCI, 1 mM EDTA, 1 mM ethylene glycol tetraacetic acid, 1% Nonidet P-40, 1% glycerol including protease and phosphatase inhibitors. Lysates were cleared by centrifugation and the supernatants were incubated with anti-HSP90 antibody (MA3-011, ThermoFisher Scientific) overnight at 4°C and A/G agarose beads for 2 h at 4°C. The immunocomplexes were washed and immunoblotted with anti-IRE1α antibody.
RNA extraction, real-time quantitative reverse transcription (RT)-PCR and RT-PCR
Total RNA was isolated using Aurum total RNA mini kit (Bio-Rad) and reverse transcribed to cDNA using the iScript cDNA synthesis kit (Bio-Rad). Real-time PCR was performed using the iTaq Universal SYBr Green Supermix (Bio-Rad). All quantitative data were normalized to 36b4. For the analysis of the XBP-1 splicing, RT-PCR was carried out with specific primers to amplify a 600-bp cDNA product that was analyzed in 3% agarose gel by electrophoresis. ACTIN-β was used as the endogenous loading control. Primer sequences for the real-time PCR and RT-PCR experiments are listed in Supplementary Table 1 (Supplementary Data) .
Immunofluorescence and confocal microscopy Cells were plated onto 18 mm 2 coverslips, fixed, permeabilized and blocked as previously described. 31 Slides were stained with an anti-BCL-2 antibody (Santa Cruz Biotechnology) at 4°C overnight, washed, incubated with secondary antibody and images were collected on an Olympus FV1000 inverted confocal 1X81 microscope.
